Marker Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Marker Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Marker Therapeutics: 7 sponsored US clinical trials, 2 recruiting.
Marker Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hodgkin's Lymphoma, Relapsed, Adult, with 1 trials.
Upper-quartile sponsor footprint
Marker Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
NCT06552416
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
NCT06549751
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
NCT04511130
Plasma Adsorption in Patients With Confirmed COVID-19
NCT04358003
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
NCT02978222
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
NCT02593227
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
What is open in the Marker Therapeutics pipeline
2 recruiting of 7 indexed (29% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Hodgkin's Lymphoma, Relapsed, Adult (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Marker Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Marker Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Marker Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Marker Therapeutics or any single study.
- 2 of Marker Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hodgkin's Lymphoma, Relapsed, Adult is the condition Marker Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hodgkin's Lymphoma, Relapsed, Adult trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Marker Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.